Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis

Mod Rheumatol. 2015;25(6):962-6. doi: 10.3109/14397595.2013.844402. Epub 2013 Oct 21.

Abstract

Macrophage activation syndrome (MAS), also known as secondary hemophagocytic lymphohistiocytosis, is mediated by cytokine overproduction from excessive activation of T lymphocytes and macrophages. We present a dermatomyositis patient with MAS, caused by hypercytokinemia. The combination of tacrolimus and plasma exchange therapy was effective in this case for treating MAS. This combination therapy is especially useful for MAS refractory to steroids.

Keywords: Dermatomyositis; Hypercytokinemia; Macrophage activation syndrome; Plasma exchange; Tacrolimus.

Publication types

  • Case Reports

MeSH terms

  • Combined Modality Therapy
  • Dermatomyositis / complications*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Macrophage Activation Syndrome / complications
  • Macrophage Activation Syndrome / drug therapy
  • Macrophage Activation Syndrome / therapy*
  • Male
  • Middle Aged
  • Plasmapheresis*
  • Tacrolimus / therapeutic use*
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Tacrolimus